NasdaqGS - Nasdaq Real Time Price USD
Revolution Medicines, Inc. (RVMD)
As of 1:25 PM EST. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
742.00
11,580.00
35,380.00
29,390.00
42,983.00
Operating Expense
653,939.00
498,765.00
293,659.00
217,398.00
153,680.00
Operating Income
-653,197.00
-487,185.00
-258,279.00
-188,008.00
-110,697.00
Net Non Operating Interest Income Expense
84,332.00
47,179.00
9,154.00
917.00
2,167.00
Other Income Expense
--
115.00
--
--
--
Pretax Income
-566,718.00
-439,891.00
-249,125.00
-187,091.00
-108,530.00
Tax Provision
343.00
-3,524.00
-420.00
--
-371.00
Net Income Common Stockholders
-567,061.00
-436,367.00
-248,705.00
-187,091.00
-110,378.00
Diluted NI Available to Com Stockholders
-567,061.00
-436,367.00
-248,705.00
-187,091.00
-110,378.00
Basic EPS
-3.66
-3.86
-3.08
-2.57
-2.01
Diluted EPS
-3.66
-3.86
-3.08
-2.57
-2.01
Basic Average Shares
159,555.24
113,149.87
80,626.53
72,806.08
54,874.12
Diluted Average Shares
159,555.24
113,149.87
80,626.53
72,806.08
54,874.12
Total Operating Income as Reported
-653,197.00
-487,185.00
-258,279.00
-188,008.00
-110,697.00
Total Expenses
653,939.00
498,765.00
293,659.00
217,398.00
153,680.00
Net Income from Continuing & Discontinued Operation
-567,061.00
-436,367.00
-248,705.00
-187,091.00
-108,159.00
Normalized Income
-570,649.97
-436,367.00
-248,705.00
-187,091.00
-108,159.00
Interest Income
84,635.00
47,482.00
9,154.00
929.00
2,238.00
Interest Expense
--
303.00
--
12.00
71.00
Net Interest Income
84,332.00
47,179.00
9,154.00
917.00
2,167.00
EBIT
-605,600.00
-439,588.00
-249,125.00
-187,079.00
-108,459.00
EBITDA
-594,305.00
-430,279.00
-239,469.00
-179,747.00
-101,914.00
Reconciled Depreciation
11,295.00
9,309.00
9,656.00
7,332.00
6,545.00
Net Income from Continuing Operation Net Minority Interest
-567,061.00
-436,367.00
-248,705.00
-187,091.00
-108,159.00
Total Unusual Items Excluding Goodwill
4,543.00
--
--
--
--
Total Unusual Items
4,543.00
--
--
--
--
Normalized EBITDA
-598,848.00
-430,279.00
-239,469.00
-179,747.00
-101,914.00
Tax Rate for Calcs
0.00
0.00
0.00
--
0.00
Tax Effect of Unusual Items
954.03
--
--
--
--
12/31/2020 - 2/13/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
KYMR Kymera Therapeutics, Inc.
44.35
+0.67%
PCVX Vaxcyte, Inc.
92.52
+7.62%
BPMC Blueprint Medicines Corporation
97.57
+2.91%
NUVL Nuvalent, Inc.
93.58
+2.64%
PTGX Protagonist Therapeutics, Inc.
42.95
+5.66%
ACLX Arcellx, Inc.
89.10
+2.16%
CRNX Crinetics Pharmaceuticals, Inc.
57.82
+3.11%
CYTK Cytokinetics, Incorporated
49.00
-1.72%
ARVN Arvinas, Inc.
25.01
+10.20%
KURA Kura Oncology, Inc.
10.51
-33.94%